Predictors of death from chronic graft-versus-host disease after bone marrow transplantation

J. R. Wingard, S. Piantadosi, Georgia Boyce Vogelsang, E. R. Farmer, Douglas Jabs, L. S. Levin, W. E. Beschorner, R. A. Cahill, D. F. Miller, D. Harrison, R. Saral, G. W. Santos

Research output: Contribution to journalArticle

Abstract

Chronic graft-v-host disease (chronic GVHD) is a frequent cause of late morbidity and death after bone marrow transplantation (BMT). The actuarial survival after onset of chronic GVHD in 85 patients was 42% (95% CI = 29%, 54%) at 10 years. Baseline characteristics present at the onset of chronic GVHD (before therapy) in 85 patients were reviewed to determine which were risk factors for death. In a multivariate proportional hazards analysis, three baseline factors emerged as independent predictors of death: progressive presentation (chronic GVHD following acute GVHD without resolution of acute GVHD; hazard ratio of 4.1, 95% CI = 2.1 to 7.8), lichenoid changes on skin histology (hazard ratio of 2.2, 95% CI = 1.1 to 4.3), and elevation of serum bilirubin > 1.2 mg/dL (hazard ratio = 2.1, 95% CI = 1.1 to 4.1). Actuarial survival of 23 chronic GVHD patients with none of these risk factors was 70% at 6 years (95% CI = 38%, 88%). Thirty-eight patients with one of these risk factors had a projected 6-year survival of 43% (95% CI = 21%, 63%). The 29 patients with any combination of two or more of these factors had a projected 6-year survival of only 20% (95% CI = 8%, 37%). Identification of baseline risk factors should facilitate design of trials of chronic GVHD therapies and assignment of high-risk patients to more aggressive innovative therapeutic regimens.

Original languageEnglish (US)
Pages (from-to)1428-1435
Number of pages8
JournalBlood
Volume74
Issue number4
StatePublished - 1989

Fingerprint

Transplantation (surgical)
Graft vs Host Disease
Bone Marrow Transplantation
Grafts
Bone
Transplants
Hazards
Survival
Histology
Acute Disease
Bilirubin
Skin
Therapeutics
Morbidity
Serum

ASJC Scopus subject areas

  • Hematology

Cite this

Wingard, J. R., Piantadosi, S., Vogelsang, G. B., Farmer, E. R., Jabs, D., Levin, L. S., ... Santos, G. W. (1989). Predictors of death from chronic graft-versus-host disease after bone marrow transplantation. Blood, 74(4), 1428-1435.

Predictors of death from chronic graft-versus-host disease after bone marrow transplantation. / Wingard, J. R.; Piantadosi, S.; Vogelsang, Georgia Boyce; Farmer, E. R.; Jabs, Douglas; Levin, L. S.; Beschorner, W. E.; Cahill, R. A.; Miller, D. F.; Harrison, D.; Saral, R.; Santos, G. W.

In: Blood, Vol. 74, No. 4, 1989, p. 1428-1435.

Research output: Contribution to journalArticle

Wingard, JR, Piantadosi, S, Vogelsang, GB, Farmer, ER, Jabs, D, Levin, LS, Beschorner, WE, Cahill, RA, Miller, DF, Harrison, D, Saral, R & Santos, GW 1989, 'Predictors of death from chronic graft-versus-host disease after bone marrow transplantation', Blood, vol. 74, no. 4, pp. 1428-1435.
Wingard, J. R. ; Piantadosi, S. ; Vogelsang, Georgia Boyce ; Farmer, E. R. ; Jabs, Douglas ; Levin, L. S. ; Beschorner, W. E. ; Cahill, R. A. ; Miller, D. F. ; Harrison, D. ; Saral, R. ; Santos, G. W. / Predictors of death from chronic graft-versus-host disease after bone marrow transplantation. In: Blood. 1989 ; Vol. 74, No. 4. pp. 1428-1435.
@article{d2b63a9e177c4589aaf0a5ca674c69ad,
title = "Predictors of death from chronic graft-versus-host disease after bone marrow transplantation",
abstract = "Chronic graft-v-host disease (chronic GVHD) is a frequent cause of late morbidity and death after bone marrow transplantation (BMT). The actuarial survival after onset of chronic GVHD in 85 patients was 42{\%} (95{\%} CI = 29{\%}, 54{\%}) at 10 years. Baseline characteristics present at the onset of chronic GVHD (before therapy) in 85 patients were reviewed to determine which were risk factors for death. In a multivariate proportional hazards analysis, three baseline factors emerged as independent predictors of death: progressive presentation (chronic GVHD following acute GVHD without resolution of acute GVHD; hazard ratio of 4.1, 95{\%} CI = 2.1 to 7.8), lichenoid changes on skin histology (hazard ratio of 2.2, 95{\%} CI = 1.1 to 4.3), and elevation of serum bilirubin > 1.2 mg/dL (hazard ratio = 2.1, 95{\%} CI = 1.1 to 4.1). Actuarial survival of 23 chronic GVHD patients with none of these risk factors was 70{\%} at 6 years (95{\%} CI = 38{\%}, 88{\%}). Thirty-eight patients with one of these risk factors had a projected 6-year survival of 43{\%} (95{\%} CI = 21{\%}, 63{\%}). The 29 patients with any combination of two or more of these factors had a projected 6-year survival of only 20{\%} (95{\%} CI = 8{\%}, 37{\%}). Identification of baseline risk factors should facilitate design of trials of chronic GVHD therapies and assignment of high-risk patients to more aggressive innovative therapeutic regimens.",
author = "Wingard, {J. R.} and S. Piantadosi and Vogelsang, {Georgia Boyce} and Farmer, {E. R.} and Douglas Jabs and Levin, {L. S.} and Beschorner, {W. E.} and Cahill, {R. A.} and Miller, {D. F.} and D. Harrison and R. Saral and Santos, {G. W.}",
year = "1989",
language = "English (US)",
volume = "74",
pages = "1428--1435",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "4",

}

TY - JOUR

T1 - Predictors of death from chronic graft-versus-host disease after bone marrow transplantation

AU - Wingard, J. R.

AU - Piantadosi, S.

AU - Vogelsang, Georgia Boyce

AU - Farmer, E. R.

AU - Jabs, Douglas

AU - Levin, L. S.

AU - Beschorner, W. E.

AU - Cahill, R. A.

AU - Miller, D. F.

AU - Harrison, D.

AU - Saral, R.

AU - Santos, G. W.

PY - 1989

Y1 - 1989

N2 - Chronic graft-v-host disease (chronic GVHD) is a frequent cause of late morbidity and death after bone marrow transplantation (BMT). The actuarial survival after onset of chronic GVHD in 85 patients was 42% (95% CI = 29%, 54%) at 10 years. Baseline characteristics present at the onset of chronic GVHD (before therapy) in 85 patients were reviewed to determine which were risk factors for death. In a multivariate proportional hazards analysis, three baseline factors emerged as independent predictors of death: progressive presentation (chronic GVHD following acute GVHD without resolution of acute GVHD; hazard ratio of 4.1, 95% CI = 2.1 to 7.8), lichenoid changes on skin histology (hazard ratio of 2.2, 95% CI = 1.1 to 4.3), and elevation of serum bilirubin > 1.2 mg/dL (hazard ratio = 2.1, 95% CI = 1.1 to 4.1). Actuarial survival of 23 chronic GVHD patients with none of these risk factors was 70% at 6 years (95% CI = 38%, 88%). Thirty-eight patients with one of these risk factors had a projected 6-year survival of 43% (95% CI = 21%, 63%). The 29 patients with any combination of two or more of these factors had a projected 6-year survival of only 20% (95% CI = 8%, 37%). Identification of baseline risk factors should facilitate design of trials of chronic GVHD therapies and assignment of high-risk patients to more aggressive innovative therapeutic regimens.

AB - Chronic graft-v-host disease (chronic GVHD) is a frequent cause of late morbidity and death after bone marrow transplantation (BMT). The actuarial survival after onset of chronic GVHD in 85 patients was 42% (95% CI = 29%, 54%) at 10 years. Baseline characteristics present at the onset of chronic GVHD (before therapy) in 85 patients were reviewed to determine which were risk factors for death. In a multivariate proportional hazards analysis, three baseline factors emerged as independent predictors of death: progressive presentation (chronic GVHD following acute GVHD without resolution of acute GVHD; hazard ratio of 4.1, 95% CI = 2.1 to 7.8), lichenoid changes on skin histology (hazard ratio of 2.2, 95% CI = 1.1 to 4.3), and elevation of serum bilirubin > 1.2 mg/dL (hazard ratio = 2.1, 95% CI = 1.1 to 4.1). Actuarial survival of 23 chronic GVHD patients with none of these risk factors was 70% at 6 years (95% CI = 38%, 88%). Thirty-eight patients with one of these risk factors had a projected 6-year survival of 43% (95% CI = 21%, 63%). The 29 patients with any combination of two or more of these factors had a projected 6-year survival of only 20% (95% CI = 8%, 37%). Identification of baseline risk factors should facilitate design of trials of chronic GVHD therapies and assignment of high-risk patients to more aggressive innovative therapeutic regimens.

UR - http://www.scopus.com/inward/record.url?scp=0024418096&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024418096&partnerID=8YFLogxK

M3 - Article

C2 - 2670000

AN - SCOPUS:0024418096

VL - 74

SP - 1428

EP - 1435

JO - Blood

JF - Blood

SN - 0006-4971

IS - 4

ER -